Table 3.
Prevalence of Most Frequently Detected Mutations at Time of Diagnosis for Subtypes A, B, C, CRF 01_AE, and CRF 02_AG in Newly Diagnosed Antiretroviral-Naive Human Immunodeficiency Virus-Infected Patients in Europe, 2008–2010
| Subtype | A (n = 224), % | B (n = 2781), % | C (n = 221), % | CRF 01_AE (n = 122), % | CRF 02_AG, % (n = 245) |
|---|---|---|---|---|---|
| NRTI mutations | |||||
| T215rev | 0.88 | 3.44 | 0.88 | 0.80 | 0 |
| M41L | 0.88 | 1.99 | 0.44 | 0.80 | 0 |
| D67N | 0 | 0.80 | 0.88 | 0 | 0 |
| K219Q | 0 | 0.62 | 0.44 | 0 | 0.72 |
| L210W | 0 | 0.58 | 0 | 0 | 0 |
| M184V | 0 | 0.29 | 0 | 0 | 0.36 |
| NNRTI mutations | |||||
| E138A | 7.89 | 3.48 | 4.82 | 2.40 | 1.81 |
| K103N | 1.32 | 1.81 | 0.88 | 1.60 | 2.17 |
| Y181C | 1.32 | 0.40 | 0 | 0 | 0.36 |
| G190A | 0 | 0.54 | 0.44 | 0 | 0 |
| K101E | 0 | 0.18 | 0.88 | 0 | 0 |
| K103S | 0 | 0.25 | 0.44 | 0 | 0 |
| PI mutations | |||||
| L90M | 0 | 0.76 | 0.44 | 0 | 0.35 |
| M46I | 0.43 | 0.24 | 0 | 0.80 | 0.70 |
| M46L | 0.87 | 0.21 | 0 | 1.60 | 0 |
| V82A | 0 | 0.17 | 0.44 | 0 | 0 |
| I54V | 0 | 0 | 0.44 | 0 | 0.70 |
The prevalence of all mutations at baseline can be found in Supplementary Table 1.
Abbreviations: CRF, circulating recombinant form; NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.